Advertisement
ABBV vs GILD
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABBV is a Buy and GILD is a Buy.
Momentum Indicator for ABBV turns positive, indicating new upward trend
ABBV saw its Momentum Indicator move above the 0 level on October 05, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 77 similar instances where the indicator turned positive. In 55 of the 77 cases, the stock moved higher in the following days. The odds of a move higher are at 71%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for ABBV just turned positive on October 07, 2026. Looking at past instances where ABBV's MACD turned positive, the stock continued to rise in 31 of 46 cases over the following month. The odds of a continued upward trend are 67%.
Following a +1.30% 3-day Advance, the price is estimated to grow further. Considering data from situations where ABBV advanced for three days, in 220 of 361 cases, the price rose further within the following month. The odds of a continued upward trend are 61%.
The Aroon Indicator entered an Uptrend today. In 231 of 358 cases where ABBV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 65%.
Bearish Trend Analysis
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 9 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABBV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 46%.
ABBV broke above its upper Bollinger Band on October 07, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 1 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 2 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock better than average.
The Tickeron Valuation Rating of 3 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ABBV's P/B Ratio (-86.072) is very low in comparison to the industry average of (-3.286). ABBV has a moderately high P/E Ratio (81.661) as compared to the industry average of (20.679). Projected Growth (PEG Ratio) (0.544) is also within normal values, averaging (5.738). Dividend Yield (0.024) settles around the average of (0.041) among similar stocks. ABBV's P/S Ratio (7.231) is slightly higher than the industry average of (4.033).
The Tickeron Price Growth Rating for this company is 13 (best 1 - 100 worst), indicating outstanding price growth. ABBV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 74 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Momentum Indicator for GILD turns positive, indicating new upward trend
GILD saw its Momentum Indicator move above the 0 level on October 14, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 84 similar instances where the indicator turned positive. In 57 of the 84 cases, the stock moved higher in the following days. The odds of a move higher are at 68%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for GILD just turned positive on October 14, 2026. Looking at past instances where GILD's MACD turned positive, the stock continued to rise in 37 of 55 cases over the following month. The odds of a continued upward trend are 67%.
Following a +6.39% 3-day Advance, the price is estimated to grow further. Considering data from situations where GILD advanced for three days, in 216 of 336 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.
The Aroon Indicator entered an Uptrend today. In 141 of 272 cases where GILD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 52%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 33 of 61 cases where GILD's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 54%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GILD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 47%.
GILD broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 9 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 23 (best 1 - 100 worst), indicating outstanding price growth. GILD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (16.407) is normal, around the industry mean (-3.286). GILD's P/E Ratio (-59.966) is considerably lower than the industry average of (20.679). Projected Growth (PEG Ratio) (2.263) is also within normal values, averaging (5.738). Dividend Yield (0.021) settles around the average of (0.041) among similar stocks. P/S Ratio (6.053) is also within normal values, averaging (4.033).
The Tickeron Seasonality Score of 35 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
ABBV | GILD | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 44 | 79 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 3 Undervalued | 24 Undervalued | |
PROFIT vs RISK RATING 1..100 | 2 | 9 | |
SMR RATING 1..100 | 1 | 96 | |
PRICE GROWTH RATING 1..100 | 13 | 23 | |
P/E GROWTH RATING 1..100 | 74 | 100 | |
SEASONALITY SCORE 1..100 | 50 | 35 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ABBV's Valuation (3) in the Pharmaceuticals Major industry is in the same range as GILD (24) in the Biotechnology industry. This means that ABBV’s stock grew similarly to GILD’s over the last 12 months.
ABBV's Profit vs Risk Rating (2) in the Pharmaceuticals Major industry is in the same range as GILD (9) in the Biotechnology industry. This means that ABBV’s stock grew similarly to GILD’s over the last 12 months.
ABBV's SMR Rating (1) in the Pharmaceuticals Major industry is significantly better than the same rating for GILD (96) in the Biotechnology industry. This means that ABBV’s stock grew significantly faster than GILD’s over the last 12 months.
ABBV's Price Growth Rating (13) in the Pharmaceuticals Major industry is in the same range as GILD (23) in the Biotechnology industry. This means that ABBV’s stock grew similarly to GILD’s over the last 12 months.
ABBV's P/E Growth Rating (74) in the Pharmaceuticals Major industry is in the same range as GILD (100) in the Biotechnology industry. This means that ABBV’s stock grew similarly to GILD’s over the last 12 months.
| ABBV | GILD | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 33% | N/A |
| Stochastic ODDS (%) | 2 days ago 47% | 2 days ago 54% |
| Momentum ODDS (%) | 2 days ago 71% | 2 days ago 68% |
| MACD ODDS (%) | 2 days ago 67% | 2 days ago 67% |
| TrendWeek ODDS (%) | 2 days ago 63% | 2 days ago 63% |
| TrendMonth ODDS (%) | 2 days ago 64% | 2 days ago 65% |
| Advances ODDS (%) | 6 days ago 61% | 7 days ago 64% |
| Declines ODDS (%) | 21 days ago 46% | 3 days ago 47% |
| BollingerBands ODDS (%) | 2 days ago 43% | 2 days ago 50% |
| Aroon ODDS (%) | 2 days ago 65% | 2 days ago 52% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ABBV’s FA Score shows that 4 FA rating(s) are green while GILD’s FA Score has 3 green FA rating(s).
- ABBV’s FA Score: 4 green, 1 red.
- GILD’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ABBV’s TA Score shows that 4 TA indicator(s) are bullish while GILD’s TA Score has 4 bullish TA indicator(s).
- ABBV’s TA Score: 4 bullish, 4 bearish.
- GILD’s TA Score: 4 bullish, 3 bearish.
Price Growth
ABBV (@Pharmaceuticals: Major) experienced а +6.01% price change this week, while GILD (@Pharmaceuticals: Major) price change was +5.81% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +0.72%. For the same industry, the average monthly price growth was -5.68%, and the average quarterly price growth was +3.76%.
Reported Earning Dates
ABBV is expected to report earnings on Oct 30, 2026.
GILD is expected to report earnings on Oct 29, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+0.72% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
ABBV and
Correlation & Price change
A.I.dvisor indicates that over the last year, ABBV has been loosely correlated with NVS. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if ABBV jumps, then NVS could also see price increases.
| Ticker / NAME | Correlation To ABBV | 1D Price Change % | ||
|---|---|---|---|---|
| ABBV | 100% | +2.26% | ||
| NVS - ABBV | 50% Loosely correlated | +2.29% | ||
| JNJ - ABBV | 49% Loosely correlated | +2.19% | ||
| AMGN - ABBV | 48% Loosely correlated | +3.29% | ||
| BMY - ABBV | 47% Loosely correlated | +4.84% | ||
| BIIB - ABBV | 41% Loosely correlated | +4.12% | ||
More | ||||